Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Immune complex–mediated antigen presentation induces tumor immunity
Khadija Rafiq, … , Amy Bergtold, Raphael Clynes
Khadija Rafiq, … , Amy Bergtold, Raphael Clynes
Published July 1, 2002
Citation Information: J Clin Invest. 2002;110(1):71-79. https://doi.org/10.1172/JCI15640.
View: Text | PDF
Article Aging

Immune complex–mediated antigen presentation induces tumor immunity

  • Text
  • PDF
Abstract

Research Article

Authors

Khadija Rafiq, Amy Bergtold, Raphael Clynes

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
OVA/IC–mediated antigen presentation in vitro induces Th1 CD4 and CD8 ce...
OVA/IC–mediated antigen presentation in vitro induces Th1 CD4 and CD8 cellular proliferation and effector differentiation of naive transgenic T cells. (a) Anti-OVA T cell responses. IC-mediated antigen presentation efficiently drives OT-I and OT-II proliferative responses in vitro. 2 × 105 CD4 OT-II and 4 × 105 CD8 OT-I cells were cultured with 104 or 2 × 104 antigen-pulsed BMDCs in 96-well culture plates. 3H-thymidine incorporation was measured between 36 and 48 hours later and expressed in cpm. OVA (10 μg/ml), OVA-containing ICs (10 μg/ml OVA and 50 μg/ml anti-OVA), or OVA (10 μg/ml) plus “irrelevant” peroxidase/antiperoxidase (PAP) complexes (50 μg/ml) were added to DCs for 48 hours prior to incubation with T cells. The results are representative of five separate experiments. (b) Cytokine production. IC-loaded BMDCs induce IFN-γ production by naive OT-I and OT-II transgenic cells. CD4 OT-II or CD8 OT-I transgenic T cells were cultured at 106/ml with 5 × 104/ml pulsed DCs in 24-well plates. IL-4 and IFN-γ production was determined by ELISA after 3–5 days of culture. The results are from two independent experiments. The sensitivity of the ELISAs were 1 pg/ml. Culture of OT-I or OT-II transgenic T cells with DCs alone (i.e., without OVA peptides or soluble OVA) did not elaborate detectable IFN-γ or IL-4.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts